A Phase 3 interventional study of Dotarem and TOF MRA in Cerebral Arterial Diseases, sponsored by Guerbet. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-16.
Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
Drug: Dotarem · Other: TOF MRA
Each subject will receive one injection of Dotarem 0.2ml/kg
Also known as: Gadoterate meglumine
Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
Technical Failure Rate
Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-061).
Time frame: 2 - 28 days
Sensitivity
Rate of true stenotic segments (i.e. with stenosis \>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).
Time frame: 2-42 days
Specificity
Rate of true non-stenotic segments (i.e. without stenosis \>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).
Time frame: 2 - 42 days
First patient first visit: 28 Oct 2009. Last patient last visit: 12 Oct 2010. Location: radiology departments
| Milestone | TOF MRA Followed by Dotarem-enhanced MRA |
|---|---|
| Started | 211 |
| Completed | 187 |
| Not completed | 24 |
Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-061).
| percentage of arterial segments | Dotarem-enhanced MRA | TOF MRA |
|---|---|---|
| Reader 1 | 3.55 (2.84 to 4.26) | 29.22 (27.48 to 30.96) |
| Reader 2 | 1.57 (1.09 to 2.04) | 17.65 (16.19 to 19.11) |
| Reader 3 | 1.68 (1.19 to 2.17) | 23.07 (21.46 to 24.68) |
Rate of true stenotic segments (i.e. with stenosis \>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).
| percentage of arterial segments | Dotarem-enhanced MRA | TOF MRA |
|---|---|---|
| Reader 1 | 70.65 (61.35 to 79.96) | 65.22 (55.48 to 74.95) |
| Reader 2 | 69.57 (60.16 to 78.97) | 73.91 (64.94 to 82.89) |
| Reader 3 | 75.00 (66.15 to 83.85) | 66.30 (56.65 to 75.96) |
Rate of true non-stenotic segments (i.e. without stenosis \>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).
| percentage of arterial segments | Dotarem-enhanced MRA | TOF MRA |
|---|---|---|
| Reader 1 | 98.03 (97.48 to 98.58) | 84.34 (82.90 to 85.79) |
| Reader 2 | 98.40 (97.90 to 98.90) | 89.51 (88.29 to 90.72) |
| Reader 3 | 98.61 (98.14 to 99.07) | 88.40 (87.13 to 89.67) |
Collected over Adverse events were collected since the patient signing the patient consent form till the end of the last visits, maximum duration is 42 days.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dotarem-enhanced MRA | — | 1/187 (0.5%) | 4/187 (2.1%) |
| TOF MRA | — | 0/187 (0%) | 0/187 (0%) |
| Computerized Tomography Angiography (CTA) | — | 1/187 (0.5%) | 0/187 (0%) |
| Patients Discontinued Without Dotarem Administration | — | 0/24 (0%) | 1/24 (4.2%) |
| Event | Dotarem-enhanced MRA | TOF MRA | Computerized Tomography Angiography (CTA) | Patients Discontinued Without Dotarem Administration |
|---|---|---|---|---|
| HypersensitivityImmune system disorders | 1/187 | 0/187 | 0/187 | 0/24 |
| Renal FailureRenal and urinary disorders | 0/187 | 0/187 | 1/187 | 0/24 |
| Event | Dotarem-enhanced MRA | TOF MRA | Computerized Tomography Angiography (CTA) | Patients Discontinued Without Dotarem Administration |
|---|---|---|---|---|
| AnxietyPsychiatric disorders | 0/187 | 0/187 | 0/187 | 1/24 |
| HeadacheNervous system disorders | 2/187 | 0/187 | 0/187 | 0/24 |
| RashSkin and subcutaneous tissue disorders | 2/187 | 0/187 | 0/187 | 0/24 |
| Age, Categorical(Participants) | TOF MRA Followed by Dotarem-enhanced MRA |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 110 |
| >=65 years | 101 |
| Age, Continuous(years) | TOF MRA Followed by Dotarem-enhanced MRA |
|---|---|
| Mean | 62.8 ± 12.7 |
| Sex: Female, Male(Participants) | TOF MRA Followed by Dotarem-enhanced MRA |
|---|---|
| Female | 105 |
| Male | 106 |
| Region of Enrollment(participants) | TOF MRA Followed by Dotarem-enhanced MRA |
|---|---|
| United States | 68 |
| Argentina | 44 |
| South Africa | 22 |
| Mexico | 25 |
| Korea, Republic of | 30 |
| Chile | 22 |
The record gives a start of Oct 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 4 years 8 months after primary completion. A results delay was requested in Nov 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine
Cerebral Arterial Diseases